ARTICLE | Clinical News
CPI-613: Phase II started
November 11, 2013 8:00 AM UTC
Cornerstone said the Comprehensive Cancer Center of Wake Forest Baptist Medical Center (Winston-Salem, N.C.) began a Phase II trial to evaluate IV CPI-613 in 4-week cycles for up to 6 cycles in about 13 patients with pancreatic cancer that cannot be removed by surgery and who have failed available therapies. Patients will initially receive CPI-613 for 5 days. Patients then will receive the compound on days 1 and 4 of weeks 2-3 on the first cycle and on days 1 and 4 of weeks 1-3 of cycles 2-6. ...